Biopsy‐proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome—Retrospective single‐center cohort study
Early response evaluation using punch biopsies at the time of the last brachytherapy can identify patients with residual tumor, which exhibit a statistically significant and clinically meaningful risk of disease progression. This risk was not reversed even in the case of a delayed hCR 6 weeks after completion of chemoradiation.
Authors
- M Mantovan
- Katharina Leitner (ORCID: https://orcid.org/0000-0002-9572-9114)
- Sergej Skvortsov (ORCID: https://orcid.org/0000-0002-5989-573X)
- J Rieker
- Irina Tsibulak (ORCID: https://orcid.org/0000-0001-6795-3015)
- Mario Brüggl
- Verena Wieser (ORCID: https://orcid.org/0000-0001-6121-2515)
- Alain G. Zeimet (ORCID: https://orcid.org/0000-0001-5306-2334)
- Christoph Ebner (ORCID: https://orcid.org/0000-0002-2033-6228)
- Barin Feroz (ORCID: https://orcid.org/0009-0001-5064-1397)
- R. Purtscheller
- Linda Ebner
- Christian Marth
Institutions
- Innsbruck Medical University (AT)
Publication Details
- Journal
- Acta Obstetricia Et Gynecologica Scandinavica
- Published
- 2025-12-21
- DOI
- https://doi.org/10.1111/aogs.70106
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00